Y-mAbs/$YMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Y-mAbs
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Ticker
$YMAB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
104
ISIN
US9842411095
Website
Y-mAbs Metrics
BasicAdvanced
$210M
-
-$0.63
0.52
-
Price and volume
Market cap
$210M
Beta
0.52
52-week high
$15.70
52-week low
$3.55
Average daily volume
200K
Financial strength
Current ratio
4.771
Quick ratio
4.117
Long term debt to equity
0.165
Total debt to equity
0.674
Profitability
EBITDA (TTM)
-23.374
Gross margin (TTM)
81.83%
Net profit margin (TTM)
-31.84%
Operating margin (TTM)
-26.87%
Effective tax rate (TTM)
1.05%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
-12.62%
Return on equity (TTM)
-29.93%
Valuation
Price to revenue (TTM)
2.332
Price to book
2.34
Price to tangible book (TTM)
2.4
Price to free cash flow (TTM)
-10.728
Free cash flow yield (TTM)
-9.32%
Free cash flow per share (TTM)
-43.16%
Growth
Revenue change (TTM)
4.92%
Earnings per share change (TTM)
27.58%
3-year revenue growth (CAGR)
30.38%
3-year earnings per share growth (CAGR)
-38.15%
What the Analysts think about Y-mAbs
Analyst ratings (Buy, Hold, Sell) for Y-mAbs stock.
Y-mAbs Financial Performance
Revenues and expenses
Y-mAbs Earnings Performance
Company profitability
Y-mAbs News
AllArticlesVideos
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
GlobeNewsWire·3 weeks ago
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
GlobeNewsWire·4 weeks ago
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Y-mAbs stock?
Y-mAbs (YMAB) has a market cap of $210M as of June 20, 2025.
What is the P/E ratio for Y-mAbs stock?
The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of June 20, 2025.
Does Y-mAbs stock pay dividends?
No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Y-mAbs dividend payment date?
Y-mAbs (YMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Y-mAbs?
Y-mAbs (YMAB) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.